Literature DB >> 22120442

Preventive pharmacological treatment --an evolving new concept in schizophrenia.

Rony Sabbag1, Raz Levin, Shany Edelman, Uriel Heresco-Levy.   

Abstract

Treatment for schizophrenia remains one of the major challenges of modern medicine. The development of innovative pharmacological approaches for this disorder can potentially alleviate tremendous human suffering and revolutionize mental health delivery systems. While current treatment guidelines for schizophrenia refer to the post-psychosis onset phase of illness, presently there is a strong resurgent interest in secondary prevention intervention applied during schizophrenia prodrome. This development stems largely from the recognition that neurobiological deficit processes associated with schizophrenia severity and chronicity are already active by the time clinical onset is recognized. Proposed preventive treatments include presently used medications and experimental compounds that hypothetically may influence ongoing pathophysiological processes earlier in their development. The future establishment of the early recognition and intervention concept in schizophrenia is critically dependent on the outcome of ongoing research assessing the feasibility of prodrome diagnosis, the efficacy of specific medications and the alleviation of the risks associated with early pharmacological treatment.

Entities:  

Mesh:

Year:  2011        PMID: 22120442

Source DB:  PubMed          Journal:  Isr J Psychiatry Relat Sci        ISSN: 0333-7308            Impact factor:   0.481


  3 in total

Review 1.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

2.  Reliability and validity of the CogState battery Chinese language version in schizophrenia.

Authors:  Na Zhong; Haifeng Jiang; Jin Wu; Hong Chen; Shuxing Lin; Yan Zhao; Jiang Du; Xiancang Ma; Ce Chen; Chengge Gao; Kenji Hashimoto; Min Zhao
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

3.  Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serine.

Authors:  Hiroko Hagiwara; Masaomi Iyo; Kenji Hashimoto
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.